New hope for lung cancer patients after other treatments fail
Disease control
Not yet recruiting
This study is testing a new oral drug called JYP0322 against standard chemotherapy for people with advanced lung cancer that has a specific genetic change (ROS1-positive) and has stopped responding to previous targeted therapies. About 207 participants will be randomly assigned t…
Phase: PHASE3 • Sponsor: Guangzhou JOYO Pharma Co., Ltd • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC